CNTB (Connect Biopharma) Forward P/E Multiple
Connect Biopharma holds a position of authority in the therapy of chronic inflammation and asthma. The company's forward P/E ratio clearly demonstrates the market cost of capital, while 0.00 expresses the current value of the metric. Experts highly value the brand's potential for international collaboration in the treatment of autoimmune pathologies. Stable demand for dermatitis treatments will ensure sustainable sales for the issuer in the future.
Analytical breakdowns for Connect Biopharma
- current price and projected stock value:
- business market valuation indicators:
- book capitalization information:
- debt and liquidity details:
Total Debt to Equity Ratio Connect Biopharma|CNTB - Long-Term Debt to Capital|Short-Term Debt to Equity Connect Biopharma|CNTB - Company Aggregate Debt|Debts to Book Capitalization Connect Biopharma Holdings|CNTB - Long-Term Debt|Company Short-Term Debts Connect Biopharma|Quick Liquidity connectbiopharm.com
- company profitability and valuation multiples indicators:
CNTB - Company Net Income|Expected Profit Connect Biopharma|CNTB - Price to Earnings Multiple|Future Price to Earnings Connect Biopharma|CNTB - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Connect Biopharma Holdings|CNTB - Profit before interest, taxes and amortization|Net earnings per share (EPS TTM) Connect Biopharma|CNTB - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months connectbiopharm.com|CNTB - Net earnings per one share growth for the current year|Expected earnings per share growth for next year Connect Biopharma
Summary company analytics:Connect Biopharma Holdings Limited
The potential of Connect Biopharma (CNTB) is based on clinical trials of anti-inflammatory drugs, making the forward P/E according to company analyst estimates a key indicator of profit expectations in the absence of current cash flow. This metric compares market capitalization with future earnings, allowing investors to assess the market's emotional resilience and recognize the risk of a fundamental business collapse in a timely manner.
Competitors of Connect Biopharma (CNTB)
Projected Price to Earnings ARGX (argenx)|BNTX (BioNTech Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple ABVX (abivax.com)|Market Cap to Projected Earnings ADMA Corp (ADMA)|PTGX - Future Price to Earnings|immunovant.com (IMVT) - Projected Price to Earnings|Kiniksa (KNSA) - Future Price to Earnings|Projected Price to Earnings Grifols SA|Projected Price to Earnings ADPT|Forward P/E Multiple Celldex Corp|Future Price to Earnings Aurinia Pharmaceuticals (AUPH)|biocryst.com - Price to Future Earnings Ratio|Forward P/E Multiple VERA (Vera Therapeutics)|Dianthus Therapeutics Inc (DNTH) - Projected Price to Earnings Ratio|Pharvaris Corp - Forward P/E Multiple|AbCellera Biologics (ABCL) - Projected Price to Earnings|Tourmaline Bio, Inc. (TRML) - Future Price to Earnings|Projected Price to Earnings Ratio precigen.com (PGEN)|Future Price to Earnings Pharming Group|Price to Future Earnings Ratio NKTR (Nektar Therapeutics Inc)|Future Price to Earnings Upstream Bio Corp (UPB)|Zenas Corp - Price to Future Earnings Ratio|Forward P/E Multiple IMNM (Immunome, Inc.)|gossamerbio.com (GOSS) - Projected Price to Earnings Ratio|KalVista Pharmaceuticals, Inc. - Forward P/E Multiple|Septerna, Inc. (SEPN) - Projected Price to Earnings|PVLA (Pieris Pharmaceuticals Inc) - Projected Price to Earnings|SVRA: Market Cap to Future Earnings Ratio|Projected Price to Earnings RIGL|ANAB: Future Price to Earnings Multiple|Forward P/E Multiple ATXS|Future Price to Earnings ENGN (enGene Holdings Inc)|Forward P/E Multiple RAPT (RAPT Therapeutics, Inc.)|Market Cap to Projected Earnings Aerovate Therapeutics, Inc. (JBIO)|ACRS - Future Price to Earnings|Projected Price to Earnings Ratio kyvernatx.com|Tiziana Life Sciences Ltd (TLSA) - Future Price to Earnings|Price to Expected Earnings Ratio CABA (Cabaletta Bio Inc.)|VTYX (Ventyx Bio) - Forward P/E Multiple|THTX: Future Price to Earnings Multiple|Forward P/E Multiple AVTX|Forward P/E Multiple eledon.com (ELDN)|Future Price to Earnings Agenus Inc. AGEN|Future Price to Earnings Multiple CLYM|ZURA - Future Price to Earnings|aTyr Pharmaceuticals (ATYR) - Projected Price to Earnings|ADAG: Forward P/E Multiple|Ikena Oncology (IMA) - Forward P/E Multiple|STTK (Shattuck Labs Inc) - Forward P/E Multiple|Projected Price to Earnings Equillium Bio (EQ)|Future Price to Earnings Immunic, Inc. (IMUX)|atarabio.com - Price to Future Earnings Ratio|InflaRx - Projected Price to Earnings|Market Cap to Future Earnings Ratio XFOR (x4pharma.com)|Adicet - Forward P/E Multiple|CELU: Future Price to Earnings|INmune Bio Corp (INMB) - Future Price to Earnings|Price to Expected Earnings Ratio BRNS (Barinthus Biotherapeutics Corp)|KZR (Kezar Life Sciences) - Forward P/E Multiple|SABS: Future Price to Earnings Multiple|Forward P/E Multiple AKTX|Forward P/E Multiple enlivex.com (ENLV)|Future Price to Earnings Q32 Bio QTTB|Future Price to Earnings Multiple GOVX|EDSA - Future Price to Earnings|ibioinc.com (IBIO) - Projected Price to Earnings|CARM: Forward P/E Multiple|XTL Biopharmaceuticals Ltd (XTLB) - Forward P/E Multiple|Projected Price to Earnings BOLT|HCWB: Future Price to Earnings Multiple|Forward P/E Multiple APVO|Market Cap to Projected Earnings AIM ImmunoTech, Inc.|Future Price to Earnings Aditxt, Inc. ADTX|GRI - Projected Price to Earnings|XRTX - Future Price to Earnings|Vyome Therapeutics (HIND) - Projected Price to Earnings|REVB (Revelation Biosciences) - Projected Price to Earnings|indaptusrx.com (INDP) - Forward P/E Multiple|Future Price to Earnings Scinai Immunotherapeutics Ltd.|Price to Future Earnings Ratio CALI (CalciMedica Corp)|Forward P/E Multiple AFMD|ALLK - Projected Price to Earnings Ratio|Forward P/E Multiple HOOK (HOOKIPA Pharma)|IGMS - Projected Price to Earnings|ITOS - Future Price to Earnings|Projected Price to Earnings Ratio Ocean Biomedical Inc|TC BioPharm (Holdings) PLC (TCBP) - Future Price to Earnings|Price to Future Earnings Ratio THRD
